Status:
COMPLETED
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
Lead Sponsor:
Baqiyatallah Medical Sciences University
Conditions:
COVID-19
Favipiravir
Eligibility:
All Genders
16-100 years
Phase:
NA
Brief Summary
This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) ...
Eligibility Criteria
Inclusion
- Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RT-PCR test for COVID-19
- Requiring hospitalization
- Patient's age between 16 and 100 years
- Signed informed consent form
Exclusion
- Receiving other antiviral medications such as (Kaletra, Ribavirin, Oseltamivir)
- Chronic liver or renal failure
- HIV; GI bleeding
- Pregnancy
- Lactation
- QT interval \> 500 ms.
Key Trial Info
Start Date :
March 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 25 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04376814
Start Date
March 29 2020
End Date
May 25 2020
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohammad Sadegh Bagheri Baghdasht
Tehran, Iran, 0